Drug Profile
NGX 5020
Latest Information Update: 21 Nov 2006
Price :
$50
*
At a glance
- Originator NeurogesX
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Nov 2006 Discontinued - Phase-I for Pain in USA (unspecified route)
- 16 Jan 2003 Phase-I clinical trials in Pain in USA (unspecified route)
- 11 Mar 2002 Preclinical trials in Pain in USA (unspecified route)